Nerve Damage

Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes

Retrieved on: 
Thursday, November 3, 2022
NASDAQ, Injury, Security (finance), Urology, IND, Elective surgery, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Toxicity, Clinical trial, FDA, Diabetic ketoacidosis, Program, Seizure, Hypoglycemia, Forward-looking statement, News, Pacific Northwest Diabetes Research Institute, Nasdaq Market Makers Antitrust Litigation, Nerve Damage, Stroke, CEO, Research, Food, Therapy, Eye disease, View, PRDC, Type 1 diabetes, U.S. Securities and Exchange Commission, Nutrient, Pancreas, Consciousness, Patient, Death, Company, Translation, Investigational New Drug, Diabetes, Immunotherapy, T1D, University, Microbiology, Type 1, Coma, Degenerative disease, Biomedical engineering, Endocrinology, Insulin, Neurology, Multimedia, Severe cognitive impairment, Commission, Immunology, Ageing, Pharmaceutical industry, Medical device

PHOENIX, Nov. 3, 2022 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), an immuno-endocrine company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug (IND) application, enabling the Company to proceed with initiating a clinical trial for Type 1 Diabetes using AlloStem™.

Key Points: 
  • The primary objective of the study (CELZ-201) is to evaluate AlloStemin patients with newly diagnosed Type 1 Diabetes.
  • "This is a milestone event for Creative Medical Technology Holdings as it marks the Company's first IND clearance from the FDA," said Timothy Warbington, CEO.
  • See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/creative-medical-technology-hol...
    SOURCE Creative Medical Technology Holdings, Inc.

Healogics® Promotes Diabetes Awareness to Improve Healing and Reduce Amputations for Diabetes-Related Wounds

Retrieved on: 
Tuesday, November 1, 2022
Awareness, Leg, Population, ADA, Amputation, Diabetic foot ulcer, American Diabetes Association, Mortality, Prediabetes, Wound healing, Diet, Obesity, Risk, Nerve Damage, COVID-19, Diabetic foot, Risk factor, Diabetes, Blister, Heredity, Patient, Multimedia, Quality of life, Pharmaceutical industry, Frankincense

JACKSONVILLE, Fla., Nov. 1, 2022 /PRNewswire/ --Asmillions of Americans living with diabetes are also living with chronic wounds that won't heal,Healogicsis raising awareness of diabetes-related wounds as part of the Healogicsninth annual Diabetes Awareness Campaign.

Key Points: 
  • JACKSONVILLE, Fla., Nov. 1, 2022 /PRNewswire/ --Asmillions of Americans living with diabetes are also living with chronic wounds that won't heal,Healogicsis raising awareness of diabetes-related wounds as part of the Healogicsninth annual Diabetes Awareness Campaign.
  • There are more than 37 million Americans currently living with diabetes, according to the American Diabetes Association (ADA).
  • Additionally, there are 96 million American adults who have prediabetes, leading to 1.4 million new diagnoses of diabetes every year.
  • Healogics recommends the following to help prevent diabetic foot ulcers:
    Early detection and specialized care from a Wound Care Center can reduce healing times and significantly reduce the risk of amputation.

The Worldwide Cosmetic Surgery Industry is Expected to Reach $201 Billion by 2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 20, 2022
Surgery, Health, Breast, Medicine, Growth, Infection, Nerve Damage, Anesthesia, Rhinoplasty, CAGR, Porter's five forces analysis, Technology, Profile, Edema, Awareness, Face, Elective surgery, ASPS, Hypoesthesia, Procedure, Benchmarking, Dentistry, Retail

The global cosmetic surgery market was valued at $67,289.1 million in 2021, and is projected to reach $201,025.5 million by 2031, registering a CAGR of 11.6% from 2022 to 2031.

Key Points: 
  • The global cosmetic surgery market was valued at $67,289.1 million in 2021, and is projected to reach $201,025.5 million by 2031, registering a CAGR of 11.6% from 2022 to 2031.
  • Cosmetic surgery is a type of plastic surgery that aims to improve a person's appearance.
  • Development of products with advanced technologies for cosmetic procedures boost demand for cosmetic surgery and provide growth opportunities for the cosmetic surgery market.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cosmetic surgery market analysis from 2021 to 2031 to identify the prevailing cosmetic surgery market opportunity.

EQS-News: New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope

Retrieved on: 
Monday, October 10, 2022
People, Quality of life, News, Muscle, Merck, Communication, Disease, Health status of White Americans, Therapy, Spinal cord, Amyotrophic lateral sclerosis, MS, Multiple sclerosis, Nerve Damage, Animal, Employment, NYSE, NASDAQ, Lists of diseases, Antibody, Cerev Del, Patient, Psychopharmacology, Research, NIH, Walking, HIV disease progression rates, ALS, Partnership, Motor neuron, Technology, Center, Immune system, SOD1, Disorder, Ketamine, Immune tolerance, National, Amyotrophy, Motor neuron disease, CNM, Advertising, CNS, Survival, Korea Disease Control and Prevention Agency, KTTA, Brain, Atrophy, Death, MRK, COVID-19, Psychiatry, Central nervous system, Neutralizing antibody, Pharmaceutical industry, Vaccine

People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.

Key Points: 
  • People suffering from incurable neurological diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) hope new therapies and drugs will arrive sooner than later.
  • MS is a potentially disabling disease affecting the brain and spinal cord the bodys central nervous system.
  • The immune system of those with MS attacks the myelin, the protective sheath covering a persons nerve fibers.
  • Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which nerves are affected.

Acasti Announces Court Dismissal of Stockholder Litigation

Retrieved on: 
Friday, September 30, 2022
Securities Exchange Act of 1934, Disability, TSX, COVID-19, Mergers and acquisitions, Bleeding, FDA, Brain, PHN, Securities Act of 1933, Neuropathic pain, Subarachnoid hemorrhage, Acquisition, Compliance, U.S. Securities and Exchange Commission, Risk, SAH, Skull, Postherpetic neuralgia, SubArachnoid Space, A-T, Private Securities Litigation Reform Act, NASDAQ, Nerve Damage, Security (finance), District court, GLOBE, Marketing, ACST, Pharmaceutical industry, Ataxia–telangiectasia

The remaining two cases were consolidated before Judge Katherine Polk Failla in the United States District Court for the Southern District of New York.

Key Points: 
  • The remaining two cases were consolidated before Judge Katherine Polk Failla in the United States District Court for the Southern District of New York.
  • Acasti and the individual defendants filed a motion to dismiss on February 25, 2022.
  • Accordingly, subject to any appeal that may be taken in response to todays ruling, all four stockholder suits filed in connection with the Merger have now been dismissed.
  • Acasti is a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases.

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

Retrieved on: 
Thursday, September 29, 2022
Securities Exchange Act of 1934, Disability, LTIP, Remuneration, Indian stock exchange, TSX, COVID-19, Director, Bleeding, FDA, Brain, PHN, Securities Act of 1933, Neuropathic pain, Subarachnoid hemorrhage, Company, CDN, Compliance, Special, Cyprus Securities and Exchange Commission, Audit committee, Risk, SAH, Skull, Exercise, Postherpetic neuralgia, SubArachnoid Space, Chair, A-T, Private Securities Litigation Reform Act, KPMG LLP, NASDAQ, Board, Nerve Damage, KPMG, Security (finance), GLOBE, Marketing, ACST, Risk management, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Qubec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the Meeting) which was held virtually on Wednesday September 28, 2022.

Key Points: 
  • LAVAL, Qubec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announced today the voting results from its Annual General and Special Meeting of Shareholders (the Meeting) which was held virtually on Wednesday September 28, 2022.
  • At the Meeting, shareholders passed an advisory (non-binding) resolution approving the compensation of Acastis named executive officers.
  • At the Meeting, disinterested shareholders approved the amendments described above to the Stock Option Plan and the Equity Incentive Plan.
  • The Governance & Human Resources Committee is now composed of Mr. Donald Olds, Chair, Mr. Vimal Kavuru and Mr. John Canan.

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Retrieved on: 
Wednesday, September 21, 2022
Securities Exchange Act of 1934, Pain scale, Disability, PK, Trial of the century, IV, COVID-19, Blood pressure, Bleeding, FDA, Brain, Phase, PHN, Drug Quality and Security Act, Betamethasone, Subarachnoid hemorrhage, Neuropathic pain, Company, Compliance, Securities Act of 1933, Heredity, Nimodipine, U.S. Securities and Exchange Commission, Patient, Risk, SAH, Skull, Bupivacaine, Postherpetic neuralgia, A-T, Pain, SubArachnoid Space, Private Securities Litigation Reform Act, NASDAQ, Nerve Damage, Interview, Security (finance), Neurodegeneration, Marketing, ACST, Disease, Fine chemical, Vaccine, Pharmaceutical industry, Ataxia–telangiectasia

Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Key Points: 
  • Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.
  • Jolly then asked about one of the Company's additional assets, GTX-104, an intravenous infusion targeting Subarachnoid Hemorrhage (SAH).
  • "At the end of the day, it's all about getting these drugs approved to treat these rare and orphan diseases."
  • All forward looking statements contained in this press release speak only as of the date on which they were made.

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

Retrieved on: 
Wednesday, September 14, 2022
Securities Exchange Act of 1934, Disability, Degenerative disease, TSX, COVID-19, Bleeding, FDA, Brain, PHN, Securities Act of 1933, Neuropathic pain, Subarachnoid hemorrhage, Company, Compliance, U.S. Securities and Exchange Commission, Risk, SAH, Skull, Postherpetic neuralgia, SubArachnoid Space, A-T, Private Securities Litigation Reform Act, NASDAQ, Nerve Damage, Security (finance), Conference, GLOBE, Marketing, ACST, Online gambling, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Qubec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.

Key Points: 
  • LAVAL, Qubec, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, announced today that it will be participating in the Lytham Partners Fall 2022 Investor Conference taking place virtually on September 28-29, 2022.
  • Management is also planning to participate in a panel at the conference titled "Orphan Drugs: Innovative Companies Addressing Rare Diseases."
  • The panel, also to be conducted virtually, will be held on Wednesday, September 28, 2022 at 2:00pm ET.
  • To arrange a meeting with management, please contact Lytham Partners at [email protected] or register at https://www.lythampartners.com/fall2022invreg/ .

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Monday, September 12, 2022
Securities Exchange Act of 1934, Disability, TSX, COVID-19, Bleeding, FDA, Brain, PHN, Drug Quality and Security Act, Neuropathic pain, Subarachnoid hemorrhage, Compliance, Securities Act of 1933, U.S. Securities and Exchange Commission, Risk, SAH, Skull, Postherpetic neuralgia, SubArachnoid Space, A-T, Private Securities Litigation Reform Act, NASDAQ, Nerve Damage, Security (finance), Conference, GLOBE, Marketing, ACST, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Qubec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced that management will virtually participate at the H.C. Wainwright 24th Annual Global Investment Conference September 12-16, 2022.

Key Points: 
  • LAVAL, Qubec, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced that management will virtually participate at the H.C. Wainwright 24th Annual Global Investment Conference September 12-16, 2022.
  • The webcasted presentation will be available on demand at the H.C. Wainwright Conference Platform for registered guests.
  • To arrange a meeting with management, please contact your H.C. Wainwright representative.
  • Acasti is a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

Retrieved on: 
Tuesday, August 2, 2022
TSX, Brain, Subarachnoid hemorrhage, Skull, ACST, Postherpetic neuralgia, Neuropathic pain, GLOBE, Bleeding, Nerve Damage, SEC, Telephone, Compliance, Private Securities Litigation Reform Act, Securities Act of 1933, Securities Exchange Act of 1934, Marketing, SubArachnoid Space, COVID-19, NASDAQ, Review, PHN, Disability, FDA, A-T, SAH, Risk, Pharmaceutical industry, Ataxia–telangiectasia

LAVAL, Quebec, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Thursday, August 11, 2022, to discuss the Company’s corporate progress and other developments, as well as financial results for first quarter 2023 ended June 30, 2022.

Key Points: 
  • A webcast of the call may be accessed at https://app.webinar.net/972kwK4obMY or on the Companys Investor Relations section of the website: https://www.acastipharma.com/investors/ .
  • A webcast replay will be available on the Companys Investors News/Events section of the website ( https://www.acastipharma.com/investors/ ) through August 11, 2023.
  • Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.
  • Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.